Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Nov 14;21(1):277.
doi: 10.1186/s13054-017-1869-9.

Angiotensin II in vasodilatory shock: lights and shadows

Elio Antonucci  1 , Sara Agosta  2 , Yasser Sakr  3
Affiliations
Comment

Angiotensin II in vasodilatory shock: lights and shadows

Elio Antonucci et al. Crit Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Comment on

  • Angiotensin II for the Treatment of Vasodilatory Shock.
    Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, Busse LW, Altaweel L, Albertson TE, Mackey C, McCurdy MT, Boldt DW, Chock S, Young PJ, Krell K, Wunderink RG, Ostermann M, Murugan R, Gong MN, Panwar R, Hästbacka J, Favory R, Venkatesh B, Thompson BT, Bellomo R, Jensen J, Kroll S, Chawla LS, Tidmarsh GF, Deane AM; ATHOS-3 Investigators. Khanna A, et al. N Engl J Med. 2017 Aug 3;377(5):419-430. doi: 10.1056/NEJMoa1704154. Epub 2017 May 21. N Engl J Med. 2017. PMID: 28528561 Clinical Trial.

References

    1. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377:419–30. doi: 10.1056/NEJMoa1704154. - DOI - PubMed
    1. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014;18:534. doi: 10.1186/s13054-014-0534-9. - DOI - PMC - PubMed
    1. Wray GM, Coakley JH. Severe septic shock unresponsive to noradrenaline. Lancet. 1995;46:1604. doi: 10.1016/S0140-6736(95)91933-3. - DOI - PubMed
    1. Antonucci E, Gleeson PJ, Annoni F, Agosta S, Orlando S, Taccone FS. Angiotensin II in refractory septic shock. Shock. 2017;47:560–6. doi: 10.1097/SHK.0000000000000807. - DOI - PubMed
    1. López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21–30. doi: 10.1097/01.CCM.0000105581.01815.C6. - DOI - PubMed